Drug Information
Drug (ID: DG00182) and It's Reported Resistant Information
Name |
Spiramycin
|
||||
---|---|---|---|---|---|
Synonyms |
Spiramycin; 8025-81-8; ST075006; Spiramycinum; Spiramycine; Provamycin; Sequamycin; Espiramicin; Rovamycin; Antibiotic 799; NSC-64393; RP 5337; Rovamycine; Prestwick_121; 5337 R.P.; Prestwick2_000745; Prestwick3_000745; AC1O4WG0; Spiramycin antibiotic complex; BPBio1_000804; SCHEMBL5032756; AKOS015896378; K430; SR-01000872632; SR-01000872632-1; I06-1973; Spiramycin, European Pharmacopoeia (EP) Reference Standard; Spiramycin from Streptomyces sp., VETRANAL(TM), analytical standard; Spiramycin, Pharmaceutical Secondary Standard
Click to Show/Hide
|
||||
Indication |
In total 1 Indication(s)
|
||||
Structure | |||||
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(4 diseases)
Bacillus infection [ICD-11: 1C4Y]
[6]
Mycobacterial diseases [ICD-11: 1B2Z ]
[7]
Streptococcal pharyngitis [ICD-11: 1B51]
[8]
Disease(s) with Resistance Information Validated by in-vivo Model for This Drug
(2 diseases)
Actinomycetoma [ICD-11: 1C43]
[9]
Bacterial infection [ICD-11: 1A00-1C4Z]
[10]
|
||||
Target | Bacterial 23S ribosomal RNA (Bact 23S rRNA) | NOUNIPROTAC | [1] | ||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
Formula |
C43H74N2O14
|
||||
IsoSMILES |
C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C
|
||||
InChI |
1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26 ,27 ,28 ,29+,30 ,31-,32+,34 ,35 ,36 ,37 ,38 ,39+,40+,41 ,42 ,43 /m1/s1
|
||||
InChIKey |
ACTOXUHEUCPTEW-JMRHEKERSA-N
|
||||
PubChem CID | |||||
TTD Drug ID | |||||
DrugBank ID |
Type(s) of Resistant Mechanism of This Drug
ADTT: Aberration of the Drug's Therapeutic Target
DISM: Drug Inactivation by Structure Modification
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-01: Infectious/parasitic diseases
Bacterial infection [ICD-11: 1A00-1C4Z]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: ErmR rRNA adenine N6-methyltransferase (ERMR) | [10] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Aeromicrobium erythreum infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Discovered Using In-vivo Testing Model | |||
In Vitro Model | Aeromicrobium erythreum strains AR18 | 2041 | ||
Aeromicrobium erythreum strains AR1807 | 2041 | |||
Aeromicrobium erythreum strains AR1848 | 2041 | |||
Aeromicrobium erythreum strains AR1849 | 2041 | |||
Aeromicrobium erythreum strains AR1850 | 2041 | |||
Aeromicrobium erythreum strains BD170 | 2041 | |||
Experiment for Molecule Alteration |
Southern blotting assay | |||
Experiment for Drug Resistance |
Disk diffusion assay | |||
Mechanism Description | Using the Ery- strain AR1807 as a recipient for plasmid-directed integrative recombination, the chromosomal ermR gene (encoding 23S rRNA methyltransferase) was disrupted, ermR-disrupted strains AR1848 and AR1849 were highly sensitive to erythromycin and the other macrolide antibiotics. Phenotypic characterizations demonstrated that ermR is the sole determinant of macrolide antibiotic resistance in A. erythreum. AR18, AR1807, and AR1850 (Ery- Ermr) were resistant to clindamycin, erythromycin, spiramycin, and tylosin (some sensitivity totylosin was observed at high concentrations). | |||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Macrolide 2'-phosphotransferase II (MPHB) | [1], [2], [3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli AG100A | 562 | ||
Escherichia coli DB10 | 562 | |||
Escherichia coli TOP10 | 83333 | |||
Escherichia coli XL1-Blue | 562 | |||
Staphylococcus aureus RN4220 | 1280 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Experiment for Drug Resistance |
Agar dilution method assay | |||
Mechanism Description | Mph enzymes inactivate macrolides by phosphorylating the 2'-OH of the essential dimethylamino sugar, preventing it from binding the ribosome, and providing the chemical rationale for the resistance phenotype. |
Mycobacterial diseases [ICD-11: 1B2Z ]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: 23S ribosomal RNA methyltransferase Erm (ERM39) | [7] | |||
Molecule Alteration | Missense mutation | Putative initiation codon GTG>CTG |
||
Resistant Disease | Mycobacterium fortuitum infection [ICD-11: 1B2Z.2] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Mycobacterium peregrinum ATCC14467 | 43304 | ||
Experiment for Molecule Alteration |
DNA sequencing assay | |||
Experiment for Drug Resistance |
Mueller-Hinton (MH) broth assay | |||
Mechanism Description | The erm genes are a diverse collection of methylases that add one or two methyl groups to the adenine at position 2058 (Escherichia coli numbering) of the 23S rRNA; this modification impairs the binding of macrolides to ribosomes, and thus reduces the inhibitory activity of these agents. |
Streptococcal pharyngitis [ICD-11: 1B51]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: Macrolide-lincosamide-streptogramin B resistance protein (ERMA) | [8] | |||
Molecule Alteration | Methylation | Macrolide-binding site on the ribosome |
||
Resistant Disease | Streptococcus pyogenes infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli AG100A | 562 | ||
Experiment for Molecule Alteration |
PCR amplification and sequence alignments assay | |||
Experiment for Drug Resistance |
Agar dilution method assay | |||
Mechanism Description | Macrolide resistance commonly occurs due to methylation of the macrolide-binding site on the ribosome by methyltransferases encoded by the erm group of genes, Induction of erm(A) occurs by translational attenuationInduction of erm(A) occurs by translational attenuation. |
Actinomycetoma [ICD-11: 1C43]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: srmA open reading frame gimA (GIMA) | [9] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Streptomyces ambbyaciens infection [ICD-11: 1C43.0] | |||
Experimental Note | Discovered Using In-vivo Testing Model | |||
In Vitro Model | Escherichia coli | 668369 | ||
Escherichia coli strain S17.1 | 1227813 | |||
Micrococcus luteus strain Cgr | 1270 | |||
Micrococcus luteus strain DSM1790 | 1270 | |||
Streptomyces ambofaciens strain ATCC 23877 | 278992 | |||
Streptomyces ambofaciens strain OS41.99 | 1954 | |||
Streptomyces ambofaciens strain OS41.99NP | 1954 | |||
Streptomyces ambofaciens strain OS81 | 1954 | |||
Streptomyces lividans strain OS456 | 1916 | |||
Experiment for Molecule Alteration |
DNA sequencing assay | |||
Experiment for Drug Resistance |
Observation of growth inhibition zones assay | |||
Mechanism Description | With UDP-[14C]glucose as the cofactor, crude S30 extracts from OS456(pOS41.90) were tested on various macrolides. Among those, chalcomycin was the most active substrate. Methymycin, tylosin, pikromycin, and rosaramicin were four of the best substrates. Oleandomycin, josamycin, and carbomycin were glycosylated to a lesser extent. Macrolides that were found to be as poor substrates of GimA as lankamycin were erythromycin and angolamycin. Spiramycin was also a very poor substrate. |
Bacillus infection [ICD-11: 1C4Y]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: 23S ribosomal RNA methyltransferase Erm34 (ERM34) | [6] | |||
Molecule Alteration | Methylation | Ribosomal methylation |
||
Resistant Disease | Bacillus clausii infection [ICD-11: 1C4Y.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Bacillus clausii ATCC 21536 | 79880 | ||
Experiment for Molecule Alteration |
Cloning experiments and gene seqencing assay | |||
Experiment for Drug Resistance |
Agar dilution assay | |||
Mechanism Description | This pattern of resistance generally due to the presence of an erm gene encoding a ribosomal methylase. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.